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Abstract
External quality assurance (EQA) programs are vital to ensure high quality and standardized results in molecular diagnostics. It is
important that EQA for quantitative analysis takes into account the variation in methodology. Results cannot be expected to be
more accurate than limits of the technology used, and it is essential to recognize factors causing substantial outlier results. The
present study aimed to identify parameters of specific importance for JAK2 V617F quantification by quantitative PCR, using
different starting materials, assays, and technical platforms. Sixteen samples were issued to participating laboratories in two EQA
rounds. In the first round, 19 laboratories from 11 European countries analyzing JAK2V617F as part of their routine diagnostics
returned results from in-house assays. In the second round, 25 laboratories from 17 countries participated. Despite variations in
starting material, assay set-up and instrumentation the laboratories were generally well aligned in the EQA program. However,
EQA based on a single technology appears to be a valuable tool to achieve standardization of the quantification of JAK2 V617F
allelic burden.
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Introduction
The discovery of the c.1849G>T mutation leading to the
p.Val617Phe (V617F) substitution in JAK2 [1–4] has been a
landmark in molecular diagnosis of the myeloproliferative
neoplasms (MPN) polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF).
Quantification of the mutation has shown that mutation bur-
den also could reflect different subtypes of MPN. The major-
ity of patients with PVor fibrotic PMF have been reported to
havemore than 50% JAK2V617Fwhile the opposite has been
seen in ET patients [5, 6]. In addition, quantification of the
allelic burden in JAK2V617F-positive patients is increasingly
used to monitor treatment response of new targeted therapies
as well as in transplanted patients [7–9].
For molecular diagnosis, it has been recommended that the
assay should be sensitive enough to detect a mutant burden
around 1% [10]. The combination of a sensitive detection and
reproducible quantification of JAK2 V617F challenges the
methodology used in a routine setting. Conventional Sanger
sequencing does not show the required sensitivity in cases
with low mutation burden, and methodologies involving next
generation sequencing are unnecessarily labor intensive and
expensive for mutation detection of a single nucleotide sub-
stitution. Instead, the use of quantitative polymerase chain
reaction (qPCR) has been shown to be a both sensitive and
cost-effective method [11] and superior in sensitivity com-
pared to qualitative methods [12]. As a step towards standard-
ization of reliable molecular diagnostics, the European
Leukemia Net (ELN) and MPN&MPNr-EuroNet have evalu-
ated performance of different allele-specific (AS)-qPCR as-
says [8]. This work, involving 12 laboratories from seven
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countries recommended a JAK2 V617F qPCR assay which
showed consistent performance across different qPCR plat-
forms [13]. Even so, variation between laboratories and dif-
ferent instrumental setups can be substantial despite the use of
the same experimental protocol. To ensure high quality and
standardized quantitative results, external quality assurance
(EQA) programs are vital. A program dedicated to JAK2
V617F detection by qPCR is advantageous since no additional
bias on quantification would be introduced by comparison to a
different methodology. MPN&MPNr-EuroNet has performed
two rounds of EQA based on qPCR assays. In addition to
providing an EQA to participating laboratories in the network,
the aim was to identify parameters critical for the quantifica-
tion of JAK2 V617F. Such factors would have a substantial
impact also on an EQA result, and thus need to be identified in
order to design a beneficial EQA program which would be
useful in clinical routine.
Materials and methods
Participants
For the first quality assurance round (QA1), 19 laboratories
from 11 countries across Europe analyzing JAK2 V617F by
qPCR as part of their routine diagnostics returned results ob-
tained with in-house assays. In the second QA (QA2), 25
laboratories from 17 countries participated.
Samples and references
Blood samples from JAK2 V617F-positive patients were col-
lected after informed consent according to the guidelines of
the Danish Regional Science Ethics Committee. In QA1, ten
blood samples were collected, aliquoted, and distributed to
participating laboratories by an overnight courier. DNA was
extracted locally from whole blood according to each partici-
pant’s standard procedure. Six participants received extra
blood and extracted DNA also from hemolyzed blood (n =
3) or granulocytes (n = 3) in addition to whole blood. In QA2,
six unknown samples prepared by spiking JAK2 V617F-
positive HEL cell line DNA into normal wild-type donor
DNA was sent out. In both QA1 and QA2, a common refer-
ence for calibration corresponding to 75%, 23%, 3%, and
0.3% JAK2 V617F was created by spiking a 648 bp PCR
fragment containing the c.1849G>T mutation into normal
wild-type donor DNA and distributed with the samples.
Droplet digital PCR (ddPCR, Bio-Rad, Hercules, CA, USA)
was used to obtain a reference value for each sample in the
trials by taking the mean of four replicates repeated three
times. In QA2, values obtained by ddPCR in a separate labo-
ratory were added to the mean as well.
Quantification of JAK2 V617F by qPCR
Copy numbers for JAK2 V617F and JAK2WTand the allelic
ratios of JAK2 V617F expressed as % [JAK2 V617F copy
number/(JAK2 WT copy number + JAK2 V617F copy num-
ber)] were determined by the participating laboratories accord-
ing to the assay used in the clinical routine. All results were
sent to one laboratory for further analysis. To determine gen-
eral variation of qPCR within an assay, data was collected
from control samples and repeatedly analyzed according to
the Larsen protocol [13] during 12 months in one laboratory.
The analysis was performed by different persons on two PCR
instruments, and batches for reagents were changed during the
12-month period. Percentage JAK2 V617F was calculated for
each sample and the coefficient of variation (CV) for the assay
was determined.
Results
Similar EQA results with different starting materials,
qPCR assays, and qPCR instruments
To identify the parameters of specific importance for causing
outliers in a JAK2 V617F EQAwhere a quantitative value of
mutation burden is determined by qPCR, different starting ma-
terials, different qPCR assays, and different technical platforms
were included. In total, 16 samples with unknown mutation
burden were issued to participating laboratories. In QA1, sam-
ples were divided into four groups based on the reference
levels of JAK2 V617F as determined by ddPCR: < 2% (n =
4), 2–10% (n = 3), 10–20% (n = 2), and > 30% (n = 2). Results
were analyzed in detail for one sample in each group.
To test starting material for the analysis, six different labo-
ratories extracted DNA from purified granulocytes or hemo-
lyzed blood in addition to whole blood. JAK2 V617F was
analyzed from both types of starting materials in parallel using
routine protocol(s). Although differences could be noted be-
tween starting materials when comparisons were made within
the same laboratory, the difference was in the same range as
between the laboratories and different assays (Fig. 1).
To study the influence of assay protocols on EQA results, 19
laboratories from 11 countries analyzing JAK2 V617F by
qPCR as part of their routine diagnostics returned results from
their assay protocol used in clinical diagnostics in QA1. One of
the laboratories returned results from two different assays yield-
ing 20 sets of data in total. Various qPCR assay protocols were
used: Larsen [13], n = 6; Lippert [5], n = 5; Ipsogen Mutaquant
kit (Qiagen, Marseille, France), n = 4; and other protocols (in-
house assays), n = 5. Although reported copy numbers in sam-
ples varied between laboratories (data not shown), the % JAK2
V617F was rather consistent across different assays (Table 1).
In QA2, 25 laboratories from 17 countries returned results. Two
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Fig. 1 Comparison of different starting materials for quantitative analysis
of JAK2 V617F on selected samples. JAK2 V617F detection was
performed in parallel using different starting materials in samples with
four different levels of JAK2V617Fmutation. One of the six participating
laboratories analyzed the samples with two different assays yielding a
total of seven sets of data. Assigned values of JAK2 V617F are
reference values as determined by ddPCR. These are indicated in the
graphs by headings and dotted lines
Table 1 % JAK2 V617F obtained using different qPCR assays
EQA1 Larsen (n = 6) Lippert (n = 5) Ipsogen (n = 4) Other* (n = 5)
ddPCR % Mean % CV% Mean % CV% Mean % CV% Mean % CV%
30 31 24 31 25 34 10 29 24
16 18 24 17 31 22 19 15 28
7.3 8.6 31 9.9 36 10 21 7.1 41
1.9 2.1 34 1.7 44 2.5 39 0.8 89
EQA2 Larsen incl. modified (n = 22) Other* (n = 5)
ddPCR % Mean % CV% Mean % CV%
66 61 14 65 17
22 19 32 22 46
4.6 4.0 44 4.5 51
1.0 0.7 34 0.8 37
*The “other” group does not include the same laboratories and protocols in EQA1 and EQA2
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of the laboratories returned results from two different assays
yielding 27 sets of data. In QA2, the majority of participating
laboratories used the Larsen assay (n = 18) or a modification of
this assay (n = 4). Five laboratories reported results obtained by
another assay. The six samples issued in QA2were divided into
the same groups as for QA1 (< 2% (n = 2), 2–10% (n = 1), 10–
20% (n = 2), and > 30% (n = 1)) and one sample from each
group was analyzed in detail. Overall, variations were similar
in QA1 and in QA2 (Table 1). Although there was a relative
consistency in quantification of JAK2 V617F allelic burdens
above 2%, a higher variation was noted in samples with low
mutation burden (< 2%).
Next, we studied whether different qPCR platforms could
introduce substantial variation. The majority of QA1 partici-
pants used instruments from Applied Biosystems (Foster City,
CA, USA). Eleven sets of data were analyzed on these instru-
ments (ABI7300/7500/7500FAST/7900HT). The remaining
laboratories used Lightcycler LC480 (Roche Applied Science,
Penzberg, Germany, n = 4), Rotorgene (3000A/Q; Corbett Life
Science, Sydney, Australia; Qiagen, n = 3), or Stratagene
(MX3000/MX3500; Agilent Technologies, Santa Clara, CA,
USA, n = 2) for analysis. For all but Applied Biosystems instru-
ments, groups were very small, which resulted in single outliers
having a substantial impact on the results. In addition, different
versions of instruments from the same manufacturer were used
in all groups. Nonetheless, no major difference depending on
qPCR instrument could be seen (Fig. 2).
For comparison, CV for the Larsen assay over a stretch of
one year was determined in one participating laboratory.
During that period of time, a control sample of 4.5% JAK2
V617F was analyzed 97 times and a sample of 13% was
analyzed 64 times on two instruments (Rotorgene Q, Fig. 3).
CV for calculated % JAK2 V617F was 26% in both cases.
To evaluate whether the differences between assays and
qPCR instruments were substantial enough to affect the result
of an EQA, z-scores were determined for selected samples in
Fig. 2 JAK2V617F results obtained with different qPCR instruments on
selected samples. Different versions of instruments were included in each
group according to text. ABI n = 11, LC n = 4, Rotorgene n = 3, and
Stratagene n = 2. Median values in each group are indicated by a black
line in boxes. Assigned values of JAK2 V617F are reference values as
determined by ddPCR. These are indicated in the graphs by headings
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QA1.A z-score between 2 and− 2was considered as satisfactory
performance, a z-score between 2 and 3 or between − 2 and − 3
was considered as a warning, and a z-score above 3 or below − 3
was considered as critical. Results showed that three participants
obtained a warning, while the remaining participants got a satis-
factory performance. None was scored as “critical” (Table 2).
Discussion
Bias altering qPCR results may occur at several steps of JAK2
V617F assays, even when laboratories use the same method-
ology. Starting material for the analysis as well as technical
platform, assay design and batch variations can influence the
results. Even among laboratories using the same qPCR proto-
col for quantitative assays, considerable variation has been
reported [14]. Standardized results are vital not only to aid in
diagnosis of patients but also in clinical, multicenter studies.
One way to test how well individual laboratories align to pre-
dicted results is through participating in EQA.Moreover, EQA
are central tools for the accreditation and assessment of labo-
ratory performance. To design a useful EQA for quantitative
analysis, it is important to take into account the variation of the
methodology in focus. If expectations of consistency in results
are set too high, beyond the limits of the technology used, there
is a risk that a well-performing laboratory will get poor or
inadequate results just because of natural variation in the
method, or because of the influence of a particular parameter
which has not been identified as important for outcome.
Therefore, it is essential to recognize factors which would
cause substantial outliers in the tests, as well as which variation
could be expected from different qPCR technical platforms.
A previous study has shown that the results obtained for the
detection of the JAK2mutationwere comparable inwhole blood
and in purified granulocytes, and that no false negative was
reported in whole blood if the qPCR assay used was able to
detect < 1% JAK2 V617F [15]. However, in this study, the alle-
lic ratio was reported to be on average 15% lower in whole
blood than in purified granulocytes; the low-average JAK2
V617F values was due to a minority of the whole blood sam-
ples. The choice of the starting material could thus be of impor-
tance in individual cases depending on the question asked. In the
present study, the starting material used for the analysis did not
affect the performance in EQA for the majority of laboratories.
In both QA1 and QA2, samples with low mutation burden
(< 2% JAK2 V617F) were included, and a greater variation
was seen for these samples. This reflects the sensitivity of the
assay and the qPCR setup in each laboratory. In addition, when
dealing with low JAK2 V617F copy numbers stochastic vari-
ation will add to the overall variation. However, for low muta-
tion burden, specificity of the assay is an equally important
issue. The background level where cross-reaction with the
wild-type allele could occur must be clearly defined by each
laboratory to avoid false positive results [10].
Fig. 3 Variation in control
samples. Repeated analysis of
control samples were performed
during a 1-year period. The upper
panel shows results from a sample
with 4.5% JAK2 V617F; the
lower panel shows results from a
sample with 13% JAK2 V617F.
SD was 1.2 and 3.5 respectively

















30 1 2 7 7 3
16 3 8 5 4
7.3 2 8 7 2 1
1.9 4 6 8 1 1
*Frequency of participants with each z-score indicated in table
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To be able to compare results, over time as well as between
laboratories, there is a need to standardize the results with
respect to the quantitative level of mutation burden. In chronic
myeloid leukemia, where the level of expression of the fusion
gene BCR-ABL1 is correlated to prognosis, a conversion fac-
tor has been established to correct for differences across lab-
oratories. This factor is used to align results to an international
scale which is anchored to clinical results [16, 17]. However,
the original conversion factor was based on the sample ex-
change with a reference laboratory and this procedure is both
time-consuming and expensive and a risk for inborn errors
due to bias cannot be ruled out. To overcome this, primary
references intended for the calibration of a secondary refer-
ence material have been established [18]. In addition, a certi-
fied reference plasmid for the calibration of BCR-ABL1 quan-
tification has been manufactured [19]. As reported in a previ-
ous international study [11], a common reference material
remains a useful tool for laboratories also for JAK2 V617F,
as it allows decreasing or suppressing differences in copy
numbers in certain laboratories. In addition, it also allows
adjustment for batch variations, e.g., due to differences in
quality of primer oligonucleotides. A first WHO reference
panel for JAK2 V617F has recently been established and is
now available [20]. This holds promise to further improve
assay standardization. With increasing clinical demands for
molecular monitoring, both EQA programs and standardized
JAK2 V617F reference material are needed to identify and
maintain validated laboratories.
In conclusion, variation in method due to the starting
material, assay set-up, or qPCR equipment did not result
in significant outliers in the EQA programs included in this
study. However, EQA based on a single technology re-
mains a valuable tool to achieve standardization of JAK2
V617F quantification.
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